Predictive data also indicate a correlation between ACSL3 expression and the immune checkpoint regulator PD-L1.<h4>Conclusion</h4>These findings underscore ACSL3 as a significant biomarker and candidate therapeutic target in HCC. Here, ACSL3 is linked to hepatocellular carcinoma.